Skip to main content

Aptevo Therapeutics Inc 8-K, filed Nov 16, 2026

Aptevo Therapeutics Inc. (APVO)

8-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 8-K

Aptevo Therapeutics Inc filed this 8-K on November 16, 2026.

Aptevo reported third-quarter 2026 results, with mipletamig achieving a 79% remission rate in high-risk TP53-mutated AML. Cash and cash equivalents were $8.3 million as of September 30, 2026, and the third-quarter net loss was $6.5 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits